High-density lipoprotein subfractions - What the clinicians need to know

Cardiology (Switzerland)

Volumn 124, Issue 2, 2013, Pages 116-125

  Pirillo, Angela ^a,b   Norata, Giuseppe Danilo ^b,c   Catapano, Alberico Luigi ^b  

^a Bassini Hospital   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Coronary heart disease; High density lipoprotein; High density lipoprotein function; High density lipoprotein subpopulations

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; LIVER TRIACYLGLYCEROL LIPASE; OMEGA 3 FATTY ACID; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PRE BETA HIGH DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIET SUPPLEMENTATION; DYSLIPIDEMIA; ENZYME ACTIVITY; GENE MUTATION; GENETIC DISORDER; HUMAN; ISCHEMIC HEART DISEASE; LIPID COMPOSITION; LIPOPROTEIN METABOLISM; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PROCESSING;

EID: 84874011888     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000346463     Document Type: Article

References (78)

1. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-1310.
2. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr., Bangdiwala S, Tyroler HA: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
3. Smith JD: Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol 2010; 30: 151-155.
4. Ansell BJ, Fonarow GC, Fogelman AM: The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 2007; 18: 427-434.
5. Camont L, Chapman MJ, Kontush A: Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 2011; 17: 594-603.
6. Norata GD, Pirillo A, Ammirati E, Catapano AL: Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis 2012; 220: 11-21.
7. Drew BG, Rye KA, Duffy SJ, Barter P, Kingwell BA: The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 2012; 8: 237-245.
8. Tian L, Fu M: The relationship between high density lipoprotein subclass profile and plasma lipids concentrations. Lipids Health Dis 2010; 9: 118.
9. Drexel H, Amann FW, Rentsch K, Neuenschwander C, Luethy A, Khan SI, Follath F: Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary artery disease. Am J Cardiol 1992; 70: 436-440.
10. Johansson J, Carlson LA, Landou C, Hamsten A: High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 1991; 11: 174-182.
11. Lamarche B, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP: Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997; 17: 1098-1105.
12. Yang Y, Yan B, Fu M, Xu Y, Tian Y: Relationship between plasma lipid concentrations and HDL subclasses. Clin Chim Acta 2005; 354: 49-58.
13. Blackburn P, Lemieux I, Lamarche B, Bergeron J, Perron P, Tremblay G, Gaudet D, Despres JP: Angiographically-Assessed coronary artery disease associates with HDL particle size in women. Atherosclerosis 2012; 223: 359-364.
14. Zeljkovic A, Vekic J, Spasojevic-Kalimanovska V, Jelic-Ivanovic Z, Bogavac-Stanojevic N, Gulan B, Spasic S: LDL and HDL subclasses in acute ischemic stroke: prediction of risk and short-term mortality. Atherosclerosis 2010; 210: 548-554.
15. Mueller O, Chang E, Deng D, Franz T, Jing D, Kincaid R, Konigshofer Y, Kratzmeier M, Mc-Nulty M, Qian H, Schneider J, Schulte H, Seedorf U, Tian X, Van Cleve M, Yang D, Assmann G: PROCAM Study: risk prediction for myocardial infarction using microfluidic high-density lipoprotein (HDL) subfractionation is independent of HDL cholesterol. Clin Chem Lab Med 2008; 46: 490-498.
16. Xian X, Ma Y, Yang DD, Huang W, Wang Y, Mueller O, Chang E, Konigshofer Y, Van-Cleve M, Yang J, Liu G: Reduced high-density lipoprotein 2b in non-obese type 2 diabetic patients analysed by a microfluidic chip method in a case-control study. Biomarkers 2009; 14: 619-623.
17. Tian L, Xu Y, Fu M, Peng T, Liu Y, Long S: The impact of plasma triglyceride and apolipoproteins concentrations on high-density lipoprotein subclasses distribution. Lipids Health Dis 2011; 10: 17.
18. Rosenbaum D, Hansel B, Bonnefont-Rousselot D, Bittar R, Girerd X, Giral P, Bruckert E: Waist circumference is a strong and independent determinant of the distribution of HDL subfractions in overweight patients with cardiovascular risk factors. Diab Vasc Dis Res 2012; 9: 153-159.
19. Tian L, Jia L, Mingde F, Tian Y, Xu Y, Tian H, Yang Y: Alterations of high density lipoprotein subclasses in obese subjects. Lipids 2006; 41: 789-796.
20. Lagos KG, Filippatos TD, Tsimihodimos V, Gazi IF, Rizos C, Tselepis AD, Mikhailidis DP, Elisaf MS: Alterations in the high density lipoprotein phenotype and HDL-Associated enzymes in subjects with metabolic syndrome. Lipids 2009; 44: 9-16.
21. Tian L, Long S, Li C, Liu Y, Chen Y, Zeng Z, Fu M: High-density lipoprotein subclass and particle size in coronary heart disease patients with or without diabetes. Lipids Health Dis 2012; 11: 54.
22. Guey LT, Pullinger CR, Ishida BY, O'Connor PM, Zellner C, Francone OL, Laramie JM, Naya-Vigne JM, Siradze KA, Deedwania P, Redberg RF, Frost PH, Seymour AB, Kane JP, Malloy MJ: Relation of increased prebeta-1 highdensity lipoprotein levels to risk of coronary heart disease. Am J Cardiol 2011; 108: 360-366.
23. Sethi AA, Sampson M, Warnick R, Muniz N, Vaisman B, Nordestgaard BG, Tybjaerg-Hansen A, Remaley AT: High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem 2010; 56: 1128-1137.
24. Suzuki M, Wada H, Maeda S, Saito K, Minatoguchi S, Seishima M: Increased plasma lipidpoor apolipoprotein A-I in patients with coronary artery disease. Clin Chem 2005; 51: 132-137.
25. Borggreve SE, De Vries R, Dullaart RP: Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003; 33: 1051-1069.
26. Rye KA, Barter PJ: Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004; 24: 421-428.
27. Tashiro J, Miyazaki O, Nakamura Y, Miyazaki A, Fukamachi I, Bujo H, Saito Y: Plasma pre beta1-HDL level is elevated in unstable angina pectoris. Atherosclerosis 2009; 204: 595-600.
28. Hirayama S, Miida T, Miyazaki O, Aizawa Y: Pre beta1-HDL concentration is a predictor of carotid atherosclerosis in type 2 diabetic patients. Diabetes Care 2007; 30: 1289-1291.
29. Lamon-Fava S, Herrington DM, Reboussin DM, Sherman M, Horvath KV, Cupples LA, White C, Demissie S, Schaefer EJ, Asztalos BF: Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol 2008; 28: 575-579.
30. Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, Brown GB, Schaefer EJ: Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003; 23: 847-852.
31. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ: High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004; 24: 2181-2187.
32. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ: Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005; 25: 2185-2191.
33. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, Schaefer EJ: Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000; 20: 2670-2676.
34. O'Brien T, Nguyen TT, Hallaway BJ, Hodge D, Bailey K, Holmes D, Kottke BA: The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease. Arterioscler Thromb Vasc Biol 1995; 15: 228-231.
35. Luc G, Bard JM, Ferrieres J, Evans A, Amouyel P, Arveiler D, Fruchart JC, Ducimetiere P: Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol 2002; 22: 1155-1161.
36. Decossin C, Castro G, Derudas B, Bertrand M, Fruchart JC, Fievet C: Subclasses of LpA-I in coronary artery disease: distribution and cholesterol efflux ability. Eur J Clin Invest 1997; 27: 299-307.
37. Asztalos BF, Demissie S, Cupples LA, Collins D, Cox CE, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ: LpA-I, LpA-I:A-II HDL and CHD-risk: The Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial. Atherosclerosis 2006; 188: 59-67.
38. Arai T, Tsukada T, Murase T, Matsumoto K: Particle size analysis of high density lipoproteins in patients with genetic cholesteryl ester transfer protein deficiency. Clin Chim Acta 2000; 301: 103-117.
39. Matsuura F, Wang N, Chen W, Jiang XC, Tall AR: HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE-And ABCG1-dependent pathway. J Clin Invest 2006; 116: 1435-1442.
40. Miwa K, Inazu A, Kawashiri M, Nohara A, Higashikata T, Kobayashi J, Koizumi J, Nakajima K, Nakano T, Niimi M, Mabuchi H, Yamagishi M: Cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells to serum is preserved in CETP-deficient patients. Clin Chim Acta 2009; 402: 19-24.
41. Plengpanich W, Le Goff W, Poolsuk S, Julia Z, Guerin M, Khovidhunkit W: CETP deficiency due to a novel mutation in the CETP gene promoter and its effect on cholesterol efflux and selective uptake into hepatocytes. Atherosclerosis 2011; 216: 370-373.
42. Calabresi L, Nilsson P, Pinotti E, Gomaraschi M, Favari E, Adorni MP, Bernini F, Sirtori CR, Calandra S, Franceschini G, Tarugi P: A novel homozygous mutation in CETP gene as a cause of CETP deficiency in a Caucasian kindred. Atherosclerosis 2009; 205: 506-511.
43. Calabresi L, Simonelli S, Gomaraschi M, Franceschini G: Genetic lecithin: cholesterol acyltransferase deficiency and cardiovascular disease. Atherosclerosis 2012; 222: 299-306.
44. Daniil G, Phedonos AA, Holleboom AG, Motazacker MM, Argyri L, Kuivenhoven JA, Chroni A: Characterization of antioxidant/anti-inflammatory properties and apoA-Icontaining subpopulations of HDL from family subjects with monogenic low HDL disorders. Clin Chim Acta 2011; 412: 1213-1220.
45. Kontush A, Chapman MJ: Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006; 58: 342-374.
46. Nobecourt E, Jacqueminet S, Hansel B, Chantepie S, Grimaldi A, Chapman MJ, Kontush A: Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 2005; 48: 529-538.
47. Bellanger N, Orsoni A, Julia Z, Fournier N, Frisdal E, Duchene E, Bruckert E, Carrie A, Bonnefont-Rousselot D, Pirault J, Saint-Charles F, Chapman MJ, Lesnik P, Le Goff W, Guerin M: Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2011; 31: 1675-1681.
48. Ottestad IO, Halvorsen B, Balstad TR, Otterdal K, Borge GI, Brosstad F, Myhre AM, Ose L, Nenseter MS, Holven KB: Triglyceride-rich HDL3 from patients with familial hypercholesterolemia are less able to inhibit cytokine release or to promote cholesterol efflux. J Nutr 2006; 136: 877-881.
49. Norata GD, Pirillo A, Catapano AL: Modified HDL: biological and physiopathological consequences. Nutr Metab Cardiovasc Dis 2006; 16: 371-386.
50. Pirillo A, Uboldi P, Bolego C, Kuhn H, Catapano AL: The 15-lipoxygenase-modified high density lipoproteins 3 fail to inhibit the TNFalpha-induced inflammatory response in human endothelial cells. J Immunol 2008; 181: 2821-2830.
51. Pirillo A, Uboldi P, Kuhn H, Catapano AL: 15-Lipoxygenase-mediated modification of high-density lipoproteins impairs SR-BI-And ABCA1-dependent cholesterol efflux from macrophages. Biochim Biophys Acta 2006; 1761: 292-300.
52. Pirillo A, Uboldi P, Ferri N, Corsini A, Kuhn H, Catapano AL: Upregulation of lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human endothelial cells by modified high density lipoproteins. Biochem Biophys Res Commun 2012; 428: 230-233.
53. Catalano G, Julia Z, Frisdal E, Vedie B, Fournier N, Le Goff W, Chapman MJ, Guerin M: Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arterioscler Thromb Vasc Biol 2009; 29: 268-275.
54. Yvan-Charvet L, Matsuura F, Wang N, Bamberger MJ, Nguyen T, Rinninger F, Jiang XC, Shear CL, Tall AR: Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007; 27: 1132-1138.
55. Bellanger N, Julia Z, Villard EF, El Khoury P, Duchene E, Chapman MJ, Fournier N, Le Goff W, Guerin M: Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy. Atherosclerosis 2012; 221: 160-168.
56. Duivenvoorden R, Fayad ZA: Safety of CETP inhibition. Curr Opin Lipidol 2012; 23: 518-524.
57. Shinkai H: Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vasc Health Risk Manag 2012; 8: 323-331.
58. Michos ED, Sibley CT, Baer JT, Blaha MJ, Blumenthal RS: Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials. J Am Coll Cardiol 2012; 59: 2058-2064.
59. Bays HE, McGovern ME: Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol 2003; 6: 179-188.
60. Sakai T, Kamanna VS, Kashyap ML: Niacin, but not gemfibrozil, selectively increases LPAI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 2001; 21: 1783-1789.
61. Pan J, Shilian P, Ishida B, Wu X, Kane JP, Malloy MJ, Charles MA: Effect of niacin on prebeta-high-density lipoprotein levels in diabetes. Metabolism 2011; 60: 292-297.
62. Dallinga-Thie GM, van Tol A, Dullaart RP: Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: role of phospholipid transfer protein. Biochim Biophys Acta 2009; 1791: 714-718.
63. Brinton EA: Search and rescue for hypotheses surviving AIM-HIGH, the niacin therapy earthquake: still problematic after the primary publication. J Clin Lipidol 2012; 6: 312-317.
64. Filippatos TD, Liberopoulos EN, Kostapanos M, Gazi IF, Papavasiliou EC, Kiortsis DN, Tselepis AD, Elisaf MS: The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab 2008; 10: 476-483.
65. Miida T, Sakai K, Ozaki K, Nakamura Y, Yamaguchi T, Tsuda T, Kashiwa T, Murakami T, Inano K, Okada M: Bezafibrate increases prebeta 1-HDL at the expense of HDL2b in hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2000; 20: 2428-2433.
66. Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B: Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-Analysis. Atherosclerosis 2011; 217: 492-498.
67. Marik PE, Varon J: Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 2009; 32: 365-372.
68. Burillo E, Martin-Fuentes P, Mateo-Gallego R, Baila-Rueda L, Cenarro A, Ros E, Civeira F: Omega-3 fatty acids and HDL. How do they work in the prevention of cardiovascular disease? Curr Vasc Pharmacol 2012; 10: 432-441.
69. Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Ryden LE, Yusuf S: n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012; 367: 309-318.
70. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS: Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-Analysis. JAMA 2012; 308: 1024-1033.
71. Kwak SM, Myung SK, Lee YJ, Seo HG: Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-Analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012; 172: 686-694.
72. Guo ZG, Li C, Zhong JK, Tu Y, Xie D: Laboratory investigation of dysfunctional HDL. Chem Phys Lipids 2012; 165: 32-37.
73. Yang DH, Konigshofer Y, Dike J, Chang E, Mueller O: Performance characteristics of a microfluidic Lab-on-Chip electrophoresis system for high-density lipoprotein (HDL) subfraction separation and measurement. Clin Chem Lab Med 2010; 48: 883-889.
74. Davidson MH, Ballantyne CM, Jacobson TA, Bittner VA, Braun LT, Brown AS, Brown WV, Cromwell WC, Goldberg RB, McKenney JM, Remaley AT, Sniderman AD, Toth PP, Tsimikas S, Ziajka PE, Maki KC, Dicklin MR: Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol 2011; 5: 338-367.
75. Sirtori CR, Calabresi L, Franceschini G, Baldassarre D, Amato M, Johansson J, Salvetti M, Monteduro C, Zulli R, Muiesan ML, Agabiti-Rosei E: Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 2001; 103: 1949-1954.
76. Sampson UK, Fazio S, Linton MF: Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep 2012; 14: 1-10.
77. Arsenault BJ, Lemieux I, Despres JP, Gagnon P, Wareham NJ, Stroes ES, Kastelein JJ, Khaw KT, Boekholdt SM: HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Atherosclerosis 2009; 206: 276-281.
78. Tian L, Long S, Fu M, Liu Y, Xu Y, Jia L: Characteristics of high-density lipoprotein subclasses distribution for subjects with desirable total cholesterol levels. Lipids Health Dis 2011; 10: 64.